Back

Clinical outcomes after the introduction of dolutegravir for second-line antiretroviral therapy in South Africa: a retrospective cohort study

2023-07-08 hiv aids Title + abstract only
View on medRxiv
Show abstract

BackgroundDolutegravir is now recommended for second-line anti-retroviral therapy (ART) in low- and middle-income countries. We compared outcomes with dolutegravir (DTG) versus the previous lopinavir/ritonavir (LPV/r) regimen in South Africa. MethodsWe used routinely collected, de-identified data from 59 South African clinics. We included people living with HIV aged [≥] 15 years with virologic failure (two consecutive viral loads [≥]1000 copies/mL) on first-line tenofovir disoproxil fumar...

Predicted journal destinations